Intended for healthcare professionals

Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study

Carlos Martinez, Themistocles L Assimes, Daniel Mines, Sophie Dell’Aniello, Samy Suissa
Table 5

 Crude and adjusted rate ratios of sudden cardiac death or near death associated with current use of venlafaxine, fluoxetine, citalopram, and dosulepin, comparing longer with shorter duration of current use. Data are number (percentage) unless otherwise specified

Cases (n=568)Controls (n=14 812)Crude odds ratioAdjusted odds ratio* (95% CI)
Venlafaxine
 <90 days2 (0.4)70 (0.5)1.001.32 (0.26 to 6.70)
 ≥90 days16 (2.8)474 (3.2)1.00 (reference)1.00 (reference)
Fluoxetine
 <90 days8 (1.4)261 (1.8)0.610.70 (0.25 to 1.93)
 ≥90 days55 (9.7)1020 (6. 9)1.00 (reference)1.00 (reference)
Citalopram
 <90 days8 (1.4)153 (1.0)1.941.81 (0.63 to 5.21)
 ≥90 days31 (5.5)926 (6. 3)1.00 (reference)1.00 (reference)
Dosulepin
 <90 days8 (1.4)207 (1.4)1.271.44 (0.50 to 4.16)
 ≥90 days27 (4.8)805 (5.4)1.00 (reference)1.00 (reference)

*Adjusted for BMI≥30, smoking status, alcohol abuse, depression severity, suicide attempt, diabetes, coronary artery bypass graft and endoscopic coronary artery procedures, supraventricular arrhythmias, left ventricular hypertrophy, coronary artery disease and angina, congestive heart failure, severe congestive heart failure, ischaemic stroke, transient ischaemic attack, peripheral vascular disease, hyperlipidaemia, hypertension, hypokalaemia, rheumatoid arthritis, epilepsy, schizophrenia, use of antipsychotics, benzodiazepine, mood stabilisers, antiarrhythmics, drugs with some evidence of prolonging QT, drugs with stronger evidence of prolonging QT, lipid regulating drugs, loop diuretics all in the year prior to the year before index date and acute myocardial infarction in the year prior index date. Because the contrasts here are limited to current users, drug specific counts of cases and controls do not sum to column totals.